Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).
Atkinson VG, Quaglino P, Aglietta M, Del Vecchio M, Depenni R, Consoli F, Bafaloukos D, Ferrucci PF, Tulyte S, Krajsová I, Ascierto PA, Gueli R, Arance A, Gogas H, Banerjee H, Saliba T, de Jong E, Neyns B. Atkinson VG, et al. Among authors: gogas h. Cancers (Basel). 2021 May 18;13(10):2466. doi: 10.3390/cancers13102466. Cancers (Basel). 2021. PMID: 34070224 Free PMC article.
Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G, Fountzilas G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D, Samantas E, Kalofonos HP, Gogas H, Pavlidis N. Pentheroudakis G, et al. Among authors: gogas h. Breast Cancer Res Treat. 2006 Jun;97(3):237-44. doi: 10.1007/s10549-005-9117-4. Epub 2005 Dec 2. Breast Cancer Res Treat. 2006. PMID: 16322882
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Gogas H, et al. N Engl J Med. 2006 Feb 16;354(7):709-18. doi: 10.1056/NEJMoa053007. N Engl J Med. 2006. PMID: 16481638 Free article. Clinical Trial.
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, Kalofonos H, Fountzilas G, Panagiotou P, Kokkalis G, Papadopoulos O, Castana O, Papadopoulos S, Stavrinidis E, Vourli G, Ioannovich J, Gogas H. Pectasides D, et al. Among authors: gogas h. J Clin Oncol. 2009 Feb 20;27(6):939-44. doi: 10.1200/JCO.2008.16.3121. Epub 2009 Jan 12. J Clin Oncol. 2009. PMID: 19139440 Clinical Trial.
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Ascierto PA, et al. Among authors: gogas h. J Transl Med. 2012 Jul 4;10:83. doi: 10.1186/1479-5876-10-83. J Transl Med. 2012. PMID: 22551296 Free PMC article.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Flaherty KT, et al. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. N Engl J Med. 2012. PMID: 22663011 Free article. Clinical Trial.
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Ascierto PA, et al. Among authors: gogas h. J Transl Med. 2013 Jun 3;11:137. doi: 10.1186/1479-5876-11-137. J Transl Med. 2013. PMID: 23731854 Free PMC article.
Who benefits most from adjuvant interferon treatment for melanoma?
Gogas H, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Schachter J, Eggermont AM, Hauschild A, Espinosa E. Gogas H, et al. Am J Ther. 2015 Jan-Feb;22(1):54-60. doi: 10.1097/MJT.0b013e31829e883d. Am J Ther. 2015. PMID: 24176884 Review.
343 results